Literature DB >> 28164568

Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.

Halaleh Shakeri, Ashraf Fakhrjou, Alireza Nikanfar, Seyyed M Mohaddes-Ardebili.   

Abstract

BACKGROUND: Promoter methylation of tumor suppressor genes is an important epigenetic alteration that occurs in the primary stages of human tumors, including breast cancer. Identification of methylated genes and their relationship to clinical features can contribute to the prognosis and early detection of tumors. In this study, we explored the methylation status of APC and BRCA1 genes and their relationship to clinical factors in breast cancer patients.
METHODS: BRCA1 and APC promoter methylation was examined by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay in formalin-fixed paraffin embedded (FFPE) breast tissue from 75 patients.
RESULTS: APC promoter methylation was detected in 30.67% breast cancer tissues and BRCA1 was methylated in 9.33% of breast tumors. Methylation of APC was associated with low histological grade (p = 0.006) and methylation of BRCA1 was related with lymph node metastasis (p = 0.017).
CONCLUSIONS: These findings suggest that the methylation status of APC and BRCA1 can be a predictive marker for early detection and better management of breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28164568     DOI: 10.7754/Clin.Lab.2016.160418

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  6 in total

1.  A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Authors:  Marta Castroviejo-Bermejo; Cristina Cruz; Alba Llop-Guevara; Sara Gutiérrez-Enríquez; Mandy Ducy; Yasir Hussein Ibrahim; Albert Gris-Oliver; Benedetta Pellegrino; Alejandra Bruna; Marta Guzmán; Olga Rodríguez; Judit Grueso; Sandra Bonache; Alejandro Moles-Fernández; Guillermo Villacampa; Cristina Viaplana; Patricia Gómez; Maria Vidal; Vicente Peg; Xavier Serres-Créixams; Graham Dellaire; Jacques Simard; Paolo Nuciforo; Isabel T Rubio; Rodrigo Dienstmann; J Carl Barrett; Carlos Caldas; José Baselga; Cristina Saura; Javier Cortés; Olivier Déas; Jos Jonkers; Jean-Yves Masson; Stefano Cairo; Jean-Gabriel Judde; Mark J O'Connor; Orland Díez; Judith Balmaña; Violeta Serra
Journal:  EMBO Mol Med       Date:  2018-12       Impact factor: 12.137

2.  NFAT1 Hypermethylation Promotes Epithelial-Mesenchymal Transition and Metastasis in Nasopharyngeal Carcinoma by Activating ITGA6 Transcription.

Authors:  Jian Zhang; Zi-Qi Zheng; Ya-Wei Yuan; Pan-Pan Zhang; Ying-Qin Li; Ya-Qin Wang; Xin-Ran Tang; Xin Wen; Xiao-Hong Hong; Yuan Lei; Qing-Mei He; Xiao-Jing Yang; Ying Sun; Jun Ma; Na Liu
Journal:  Neoplasia       Date:  2019-02-15       Impact factor: 5.715

3.  Diet, Sports, and Psychological Stress as Modulators of Breast Cancer Risk: Focus on OPRM1 Methylation.

Authors:  Liangliang Li; Shuo Li; Shidong Qin; Yu Gao; Chao Wang; Jinghang Du; Nannan Zhang; Yanbo Chen; Zhen Han; Yue Yu; Fan Wang; Yashuang Zhao
Journal:  Front Nutr       Date:  2021-12-08

4.  Early diagnostic potential of APC hypermethylation in esophageal cancer.

Authors:  Bujiang Wang; Haojun Song; Haizhong Jiang; Yangbo Fu; Xiaoyun Ding; Chongchang Zhou
Journal:  Cancer Manag Res       Date:  2018-02-01       Impact factor: 3.989

5.  BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.

Authors:  Olafur A Stefansson; Holmfridur Hilmarsdottir; Kristrun Olafsdottir; Laufey Tryggvadottir; Asgerdur Sverrisdottir; Oskar T Johannsson; Jon G Jonasson; Jorunn E Eyfjord; Stefan Sigurdsson
Journal:  JNCI Cancer Spectr       Date:  2019-12-11

6.  The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis.

Authors:  Shu Li; Yong He; Chunli Li; Xing Liu; Yan Shen; Yang Wu; Ningjing Bai; Qiuhong Li
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.